AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

AROA BIOSURGERY LIMITED Call Transcript 2025

Oct 8, 2025

64426_rns_2025-10-08_62ed3a35-2430-42ec-984f-3f63836aff5a.pdf

Call Transcript

Open in viewer

Opens in your device viewer

==> picture [107 x 27] intentionally omitted <==

AROA BIOSURGERY Q UARTERLY RESULTS WEBINAR

Soft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX, AROA’ or the ‘Company’) is pleased to announce it will hold a webinar with CEO Brian Ward and CFO James Agnew on Thursday 16 October, at 9 AM AEDT, to discuss the September Quarterly Results which will be released premarket on the same day.

Investors and interested parties can register to attend the webinar via the following link:

https://us02web.zoom.us/webinar/register/WN_AGeUmaqRTB D_TZV2p1ECA

Questions can be submitted before the webinar to [email protected] or during the webinar using the Q&A function on Zoom.

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

About Aroa Biosurgery:

Aroa Biosurgery is a soft-tissue regeneration company committed to ‘unlocking regenerative healing for everybody’. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. Over 7 million AROA products have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio, Inc. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). www.aroa.com

Contact